Hypocretin-Receptor Antagonists for Treatment of Methamphetamine Use Disorder
2022
- 61Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage61
- Abstract Views61
Lecture / Presentation Description
The hypocretin/orexin (HCRT) system is associated with compulsive stimulant drug use, involving both HCRT-receptor 1 (-R1) and HCRT-receptor 2 (-R2). Few studies, however, have examined the role of HCRT-R2 or combined HCRT-R1/2 on compulsive methamphetamine (METH) taking behavior. In thus study, we examine the effects of HCRT R1, R2, and R1/2 antagonists on compulsive METH self-administration, as modeled by escalated intake in rats allowed extended access to the drug. Three cohorts of male rats were allowed either short (1h; ShA; n=7-10/cohort) and long (12h; LgA; n=7-9/cohort) access to METH intravenous self-administration for 14 sessions (fixed ratio 1 schedule). Each cohort of rats was systemically administered a single- or dual-HCRT-R antagonist 30 min prior to drug-taking operant testing in a latin-square design: cohort 1, selective HCRT-R1 antagonist (RTIOX-276; RTI-R1; 0, 10, and 20 mg/kg); cohort 2, selective HCRT-R2 antagonist (JNJ-10397049; JNJ-R2; 0, 10, and 20 mg/kg); and cohort 3, dual HCRT-R1/2 antagonist (Suvorexant; SUV-R1/2; 0, 30, and 60 mg/kg). RTI-R1 and SUV-R1/2 dose-dependently reduced METH intake in LgA (p<0.01, p<0.05), but not ShA (p=0.14, p=0.06), rats in the first hour. Administration of JNJ-R2, however, had no effect on METH intake in the first hour in either ShA (p=0.58) or LgA (p=0.58), but had deferred effects in LgA rats reducing overall METH intake over the full 6 h session (p<0.05). Beam breaks were significantly reduced following RTI-R1 (p<0.05) and SUV-R1/2 (p<0.05) in ShA rats only, although both JNJ-R2 (p<0.05) and SUV-R1/2 (p<0.05) reduced beam breaks in METH naïve rats, indicating a possible confound of generalized effects on locomotor. Combined, these results suggest HCRT-R1 neurotransmission, in particular, may contribute to compulsive METH taking associated with stimulant use disorder. Future studies will investigate the contribution of HCRT to pervasive compulsive METH use after a period of drug abstinence.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know